Related references
Note: Only part of the references are listed.Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI853520
Remy B. Verheijen et al.
TARGETED ONCOLOGY (2019)
Phase I Study of the Focal Adhesion Kinase Inhibitor BI853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
Toshihiko Doi et al.
TARGETED ONCOLOGY (2019)
Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies
Maja J. A. de Jonge et al.
TARGETED ONCOLOGY (2019)
FAK inhibitors in Cancer, a patent review
Peng-Cheng Lv et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2018)
Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype
Ulrich A. Hirt et al.
ONCOGENESIS (2018)
Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer.
Andrea Wang-Gillam et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors
J. C. Soria et al.
ANNALS OF ONCOLOGY (2016)
Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer
Grant A. Howe et al.
PLOS ONE (2016)
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors
Suzanne F. Jones et al.
INVESTIGATIONAL NEW DRUGS (2015)
A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors
Hendrik-Tobias Arkenau et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review
Ekambaram Shanthi et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2014)
Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship
Irina M. Shapiro et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
FAK in cancer: mechanistic findings and clinical applications
Florian J. Sulzmaier et al.
NATURE REVIEWS CANCER (2014)
Phase 1/1b study of the FAK inhibitor defactinib (VS-6063) in combination with weekly paclitaxel for advanced ovarian cancer.
Manish R. Patel et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors
Jeffrey R. Infante et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Share Paper
